RecruitingEarly Phase 1NCT06792799

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA Chimeric Antigen Receptor NK Cells in the Treatment of B Cell-related Autoimmune Diseases in Children

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Enrollment

36 participants

Start Date

Jan 30, 2025

Study Type

INTERVENTIONAL

Conditions

Autoimmune Diseases Systemic Lupus Erthematosus Multi-Drug Resistant Nephrotic Syndrome IgAN - IgA Nephropathy

Summary

this is an investigator-initiated trial aimed at evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Patients With B cell mediated autoimmune disease.

Eligibility

Min Age: 3 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called anti-CD19/BCMA CAR NK cells (KN5601) for people with autoimmune diseases, igan - iga nephropathy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 3 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALanti-CD19/BCMA CAR NK cells (KN5601)

Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19/BCMA CAR NK cells (KN5601) will infused in each group using dose-escalation strategy.